{"id":"W4410140470","doi":"10.1182/bloodadvances.2025016042","title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Astellas Pharma; National Institute for Health and Care Research; National Cancer Institute; Incyte; Sanofi; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Bosutinib; Tolerability; Discontinuation; Medicine; Adverse effect; Internal medicine; Oncology; Myeloid leukemia; Imatinib; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002311413,0.0002239775,0.0006659657,0.0003440398,0.0000179143,0.000011394,0.0001463188,0.0001364013,0.0001466913],"category_scores_gemma":[0.0003316422,0.0002143128,0.0001241041,0.0007025817,0.000104107,0.0001764901,0.00007958733,0.0002444561,0.00002510504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002287628,"about_ca_system_score_gemma":0.0004572608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000288923,"about_ca_topic_score_gemma":0.001625001,"domain_scores_codex":[0.9982035,0.0000609599,0.0006081605,0.0004428238,0.0002798078,0.0004047437],"domain_scores_gemma":[0.999148,0.0001689997,0.00009528203,0.0004541035,0.00005301309,0.00008056778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00508619,0.001707172,0.9355319,0.0008116534,0.0003179804,0.001406262,0.002269649,0.0001477153,0.01142352,0.0001648255,0.0001456405,0.04098751],"study_design_scores_gemma":[0.04270364,0.00111068,0.9092221,0.002393382,0.0003391248,0.00002233302,0.0003541232,0.0001686681,0.02724552,0.0005170871,0.01553976,0.0003836217],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913312,0.005415776,0.000004290674,0.000487609,0.0002917256,0.0006019541,0.00002182162,0.00004166082,0.001803928],"genre_scores_gemma":[0.9930934,0.0005728311,0.001627229,0.0002788088,0.00005764479,0.000105929,0.00002674372,0.00002643374,0.004211008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04060389,"threshold_uncertainty_score":0.8739424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009538012546709346,"score_gpt":0.2806488671159375,"score_spread":0.2711108545692281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}